|
| | 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5E)- Basic information |
| Product Name: | 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5E)- | | Synonyms: | 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5E)-;Tafluprost Impurity 21;Isopropyl (E)-7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate;Latanoprost Impurity 14;(E)-isopropyl 7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl)hept-5-enoate;1-Methylethyl (5E)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoate;Tafluprost Impurity DCP-2 | | CAS: | 1563176-58-8 | | MF: | C25H34F2O5 | | MW: | 452.53 | | EINECS: | | | Product Categories: | | | Mol File: | 1563176-58-8.mol | ![5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5E)- Structure](CAS/20200331/GIF/1563176-58-8.gif) |
| | 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5E)- Chemical Properties |
| Boiling point | 552.9±50.0 °C(Predicted) | | density | 1.186±0.06 g/cm3(Predicted) | | pka | 14.48±0.70(Predicted) |
| | 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5E)- Usage And Synthesis |
| Uses | 5,6-trans-Tafluprost is an impurity of Tafluprost T004820(M), which is a novel prostanoid used in the treatment of glaucoma and is the first prostanoid to be released in a preservative free-formula. |
| | 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5E)- Preparation Products And Raw materials |
|
